Andelyn Biosciences Inc., a patient-focused gene therapy Contract Development and Manufacturing Organization, will help the INADcure Foundation bring the first-ever gene therapy for the treatment of Infantile Neuroaxonal Dystrophy (INAD) to clinical trials.   Infantile Neuroaxonal Dystrophy (INAD) is a rare inherited neurological disorder caused by mutations in a gene called PLA2G6 that encodes for an enzyme known as Phospholipase A2. The disease leads to neurodegeneration in the nervous syste...